A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Principal Investigator

Prof Adam Mead

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1007189